The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
The supplements are made using only vegetarian-sourced ingredients
Subscribe To Our Newsletter & Stay Updated
